SalvaRx Group plc

Equities

SALV

IM00BZ4SS228

Biotechnology & Medical Research

Delayed London S.E. Other stock markets			5-day change	1st Jan Change
- ^GBX	-.--%		-47.06%	-.--%

2019	SalvaRx Evaluates Takeover Opportunities	CI
2019	Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019	CI

SalvaRx Limited announced that it has received £0.43 million in funding from 3Legs Resources plc and other investors.

September 29, 2015

SalvaRx Limited announced that it has received £430,000 in an equity round of funding on September 30, 2015. 3Legs Resources plc, a new investor invested £215,000 for 11.1% stake in the company. Returning investor Jim Mellon and Greg Bailey invested £215,000 in the company.

Latest news about SalvaRx Group plc

SalvaRx Evaluates Takeover Opportunities	19-09-26	CI
Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019	19-09-26	CI
Salvarx Group plc Reports Earnings Results for the Full Year Ended December 31, 2018	19-06-28	CI
Portage Biotech Inc. (OTCPK:PTGE.F) completed the acquisition of SalvaRx Limited from SalvaRx Group plc, James Mellon and Greg Baile.	19-01-07	CI
SalvaRx Group plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018	18-09-27	CI
Portage Biotech Inc. (OTCPK:PTGE.F) (‘Portage’) entered into a conditional sale agreement to acquire SalvaRx Limited from SalvaRx Group plc, James Mellon and Greg Baile for $80.5 million.	18-08-13	CI
SalvaRx Group plc Announces Consolidated Earnings Results for the Year Ended December 31, 2017	18-06-28	CI
SalvaRx Seeks Acquisitions	18-06-28	CI
SalvaRx Announces an Unsecured $1 Million Loan	18-06-26	CI
SalvaRx Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2017	17-09-27	CI
SalvaRx Group plc Announces Final Audited Consolidated Earnings Results for the Year Ended December 31, 2016	17-06-30	CI
SalvaRx Seeks Investments	17-06-30	CI
SalvaRx Group plc Treats First Patient INT230-6 as Part of A Phase 1/2 International Clinical Study	17-05-30	CI
SalvaRx Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016	16-09-13	CI
Salvarx Group plc Announces Audited Consolidated Earnings Results for the Year Ended 31 December 2015	16-06-27	CI
SalvaRx Seeks Acquisitions	16-06-27	CI
Intensity Therapeutics, Inc. announced that it has received $10 million in funding from Batterson Venture Capital, LLC, Vcapital, Inc., Seed Innovations Limited, SalvaRx Group plc	16-06-25	CI
SalvaRx Limited completed the acquisition of 3Legs Resources plc from BlackRock Investment Management (UK) Limited, British Polar Engines Ltd., Pires Investments PLC, Port Erin Biopharma Investments Limited and other shareholders in a reverse merger transaction.	16-03-22	CI
SalvaRx Limited signed non-binding heads of terms to acquire 3Legs Resources plc from BlackRock Investment Management (UK) Limited, British Polar Engines Ltd., Pires Investments PLC, Port Erin Biopharma Investments Limited and other shareholders in a reverse merger transaction.	15-11-03	CI
SalvaRx Limited announced that it has received £0.43 million in funding from 3Legs Resources plc and other investors.	15-09-29	CI

Chart SalvaRx Group plc

Duration

Period

More charts

Company Profile

- SalvaRx Group Plc is a Isle of Man-based company. The Company engaged in drug discovery and development, focused on immune oncology. The Company invests in novel cancer immuno-therapies and provides its portfolio companies with operational support ranging from direct operation of subsidiaries to advisory or part-time involvement in more established companies.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SALVARX GROUP PLC	-.--%	2.16M
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	113B
REGENERON PHARMACEUTICALS, INC.	+10.21%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.90%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.17%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.52B

Bio Therapeutic Drugs